Sep. 10 at 2:29 PM
Cantor reiterated
$BCAX at Overweight and said -- We continue to believe that BCAX shares remain meaningfully undervalued given ficerafusp's potential to address the large and underserved HPV-negative HNSCC market.
MRUS -
$GMAB $JNJ PYXS MRK BMY LLY
Cantor added—The company's
$1B EV is well below the
$8B GMAB (NC) paid for competitor MRUS last fall, and our
$1.5B peak sales forecast in 1L R/M HPV-negative HNSCC supports severalfold upside from current levels.
We believe growing anticipation of the mid-2027 Phase 3 interim results could drive continued share appreciation.
